← All trials
NCT04901689
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 23, 2021
- Primary completion
- Feb 28, 2022
- Completion date
- Feb 28, 2022
- First posted
- May 25, 2021
- Last posted
- Oct 28, 2021
- Enrollment
- 316
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Albert Einstein Israelite HospitalLead sponsor
- CytoDyn, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.